{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T04:03:55Z","timestamp":1789790635449,"version":"4.0.1"},"reference-count":19,"publisher":"Pharmaceutical Society of Japan","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biological &amp; Pharmaceutical Bulletin","Biol. Pharm. Bull."],"published-print":{"date-parts":[[2026,9,15]]},"DOI":"10.1248\/bpb.b26-00200","type":"journal-article","created":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T22:12:49Z","timestamp":1789423969000},"page":"1524-1528","source":"Crossref","is-referenced-by-count":0,"title":["Pharmacological Activity of Motugivatrep, a Novel Antagonist of Transient Receptor Potential Cation Channel Subfamily V Member 1"],"prefix":"10.1248","volume":"49","author":[{"given":"Tomoka","family":"Uemura","sequence":"first","affiliation":[{"name":"Research &amp; Development Division, Senju Pharmaceutical Co., Ltd., 6\u20134\u20133 Minatojima-Minamimachi, Chuo-ku, Kobe 650\u20130047, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideharu","family":"Uchida","sequence":"additional","affiliation":[{"name":"Research Division, Mochida Pharmaceutical Co., Ltd., 722 Uenohara, Jimba, Gotemba, Shizuoka 412\u20138524, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chika","family":"Higashi","sequence":"additional","affiliation":[{"name":"Research Division, Mochida Pharmaceutical Co., Ltd., 722 Uenohara, Jimba, Gotemba, Shizuoka 412\u20138524, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken-ichi","family":"Amano","sequence":"additional","affiliation":[{"name":"Research Division, Mochida Pharmaceutical Co., Ltd., 722 Uenohara, Jimba, Gotemba, Shizuoka 412\u20138524, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsuhiro","family":"Kanda","sequence":"additional","affiliation":[{"name":"Research &amp; Development Division, Senju Pharmaceutical Co., Ltd., 6\u20134\u20133 Minatojima-Minamimachi, Chuo-ku, Kobe 650\u20130047, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"163","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1) Zhang M, Ma Y, Ye X, Zhang N, Pan L, Wang B. TRP (transient receptor potential) ion channel family: structures, biological functions and therapeutic interventions for diseases. <i>Signal Transduct. Target. Ther.<\/i>, <b>8<\/b>, 261 (2023).","DOI":"10.1038\/s41392-023-01464-x"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2) Fakih D, Migeon T, Moreau N, Baudouin C, R\u00e9aux-Le Goazigo A, M\u00e9lik Parsadaniantz S. Transient receptor potential channels: important players in ocular pain and dry eye disease. <i>Pharmaceutics<\/i>, <b>14<\/b>, 1859 (2022).","DOI":"10.3390\/pharmaceutics14091859"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3) Pan Z, Wang Z, Yang H, Zhang F, Reinach PS. TRPV1 activation is required for hypertonicity-stimulated inflammatory cytokine release in human corneal epithelial cells. <i>Invest. Ophthalmol. Vis. Sci.<\/i>, <b>52<\/b>, 485\u2013493 (2011).","DOI":"10.1167\/iovs.10-5801"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4) Masuoka T, Yamashita Y, Nakano K, Takechi K, Niimura T, Tawa M, He Q, Ishizawa K, Ishibashi T. Chronic tear deficiency sensitizes transient receptor potential vanilloid 1-mediated responses in corneal sensory nerves. <i>Front. Cell. Neurosci.<\/i>, <b>14<\/b>, 598678 (2020).","DOI":"10.3389\/fncel.2020.598678"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5) Wolffsohn JS, Ben\u00edtez-Del-Castillo JM, Loya-Garcia D, Inomata T, Iyer G, Liang L, Pult H, Sabater AL, Starr CE, Vehof J, Wang MTM, Chen W, Craig JP, Dogru M, Perez VL, Stapleton F, Sullivan DA, Jones L. TFOS DEWS III: diagnostic methodology. <i>Am. J. Ophthalmol.<\/i>, <b>279<\/b>, 387\u2013450 (2025).","DOI":"10.1016\/j.ajo.2025.05.033"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6) Holland EJ, Darvish M, Nichols KK, Jones L, Karpecki PM. Efficacy of topical ophthalmic drugs in the treatment of dry eye disease: a systematic literature review. <i>Ocul. Surf.<\/i>, <b>17<\/b>, 412\u2013423 (2019).","DOI":"10.1016\/j.jtos.2019.02.012"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7) Tang HB, Nakata Y. The activation of transient receptor potential vanilloid receptor subtype 1 by capsaicin without extracellular Ca<sup>2+<\/sup> is involved in the mechanism of distinct substance P release in cultured rat dorsal root ganglion neurons. <i>Naunyn Schmiedebergs Arch. Pharmacol.<\/i>, <b>377<\/b>, 325\u2013332 (2008).","DOI":"10.1007\/s00210-007-0211-5"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8) Yang T, Zhou Y, Ma B, Duan H, Liu R, Zhao L, Qi H. Elevated neuropeptides in dry eye disease and their clinical correlations. <i>Cornea<\/i>, <b>42<\/b>, 557\u2013564 (2023).","DOI":"10.1097\/ICO.0000000000003069"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9) Vijayvergiya V, Acharya S, Wilson SP, Schmidt JJ. Measurement of ensemble TRPV1 ion channel currents using droplet bilayers. <i>PLOS ONE<\/i>, <b>10<\/b>, e0141366 (2015).","DOI":"10.1371\/journal.pone.0141366"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10) Kistner K, Siklosi N, Babes A, Khalil M, Selescu T, Zimmermann K, Wirtz S, Becker C, Neurath MF, Reeh PW, Engel MA. Systemic desensitization through TRPA1 channels by capsazepine and mustard oil\u2014a novel strategy against inflammation and pain. <i>Sci. Rep.<\/i>, <b>6<\/b>, 28621 (2016).","DOI":"10.1038\/srep28621"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11) Mogi M, Mendonza AE, Chastain J, Demirs JT, Medley QG, Zhang Q, Papillon JPN, Yang J, Gao Y, Xu Y, Stasi K. Ocular pharmacology and toxicology of TRPV1 antagonist SAF312 (Libvatrep). <i>Transl. Vis. Sci. Technol.<\/i>, <b>12<\/b>, 5 (2023).","DOI":"10.1167\/tvst.12.9.5"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12) Parra A, Madrid R, Echevarria D, Del Olmo S, Morenilla-Palao C, Acosta MC, Gallar J, Dhaka A, Viana F, Belmonte C. Ocular surface wetness is regulated by TRPM8-dependent cold thermoreceptors of the cornea. <i>Nat. Med.<\/i>, <b>16<\/b>, 1396\u20131399 (2010).","DOI":"10.1038\/nm.2264"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13) Koskim\u00e4ki S, Tojkander S. TRPV4\u2014a multifunctional cellular sensor protein with therapeutic potential. <i>Sensors<\/i>, <b>24<\/b>, 6923 (2024).","DOI":"10.3390\/s24216923"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14) Rahman MM, Jo YY, Kim YH, Park CK. Current insights and therapeutic strategies for targeting TRPV1 in neuropathic pain management. <i>Life Sci.<\/i>, <b>355<\/b>, 122954 (2024).","DOI":"10.1016\/j.lfs.2024.122954"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15) Sugiura T, Bielefeldt K, Gebhart GF. TRPV1 function in mouse colon sensory neurons is enhanced by metabotropic 5-hydroxytryptamine receptor activation. <i>J. Neurosci.<\/i>, <b>24<\/b>, 9521\u20139530 (2004).","DOI":"10.1523\/JNEUROSCI.2639-04.2004"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16) Motter AL, Ahern GP. TRPV1-null mice are protected from diet-induced obesity. <i>FEBS Lett.<\/i>, <b>582<\/b>, 2257\u20132262 (2008).","DOI":"10.1016\/j.febslet.2008.05.021"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17) B\u00edr\u00f3 T, Bodo E, Telek A, Geczy T, Tychsen B, Kovacs L, Paus R. Hair cycle control by vanilloid receptor-1 (TRPV1): evidence from TRPV1 knockout mice. <i>J. Invest. Dermatol.<\/i>, <b>126<\/b>, 1909\u20131912 (2006).","DOI":"10.1038\/sj.jid.5700321"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18) Zhao Y, Wei J, Cheng P, Ma J, Liu B, Xiong M, Gao T, Yao J, Sun T, Li Z. The involvement of TRPV1 in the apoptosis of spermatogenic cells in the testis of mice with cryptorchidism. <i>Cell Death Discov.<\/i>, <b>11<\/b>, 135 (2025).","DOI":"10.1038\/s41420-025-02447-3"},{"key":"19","unstructured":"19) Hori Y, Wada T, Omatsu K, <i>et al<\/i>. Efficacy and safety of SJP-0132 in patients with dry eye disease: a phase 2b randomized, double-masked, dose-finding study. <i>Am. J. Ophthalmol.<\/i>, <b>283<\/b>, 163\u2013175 (2026)."}],"container-title":["Biological and Pharmaceutical Bulletin"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/49\/9\/49_b26-00200\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T03:27:47Z","timestamp":1789788467000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/49\/9\/49_b26-00200\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,15]]},"references-count":19,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1248\/bpb.b26-00200","relation":{},"ISSN":["0918-6158","1347-5215"],"issn-type":[{"value":"0918-6158","type":"print"},{"value":"1347-5215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,15]]},"article-number":"b26-00200"}}